Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naive and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients

Trial Profile

A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naive and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2019

At a glance

  • Drugs Abiraterone acetate (Primary) ; Dexamethasone; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Sponsors Janssen
  • Most Recent Events

    • 04 Jun 2019 Results assessing association of plasma DNA repair deficient (DRD) status with clinical outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone acetate plus prednisone/dexamethasone, were presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 31 Aug 2018 Biomarkers information updated
    • 22 Jun 2018 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top